RNAC vs. APGE, AMPH, TARS, IOVA, IRON, IBRX, WVE, BLTE, GLPG, and ARQT
Should you be buying Cartesian Therapeutics stock or one of its competitors? The main competitors of Cartesian Therapeutics include Apogee Therapeutics (APGE), Amphastar Pharmaceuticals (AMPH), Tarsus Pharmaceuticals (TARS), Iovance Biotherapeutics (IOVA), Disc Medicine (IRON), ImmunityBio (IBRX), Wave Life Sciences (WVE), Belite Bio (BLTE), Galapagos (GLPG), and Arcutis Biotherapeutics (ARQT). These companies are all part of the "pharmaceutical products" industry.
Cartesian Therapeutics vs.
Apogee Therapeutics (NASDAQ:APGE) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their community ranking, analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.
Cartesian Therapeutics received 8 more outperform votes than Apogee Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Apogee Therapeutics an outperform vote while only 94.12% of users gave Cartesian Therapeutics an outperform vote.
Apogee Therapeutics has a beta of 2.26, suggesting that its stock price is 126% more volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500.
Apogee Therapeutics has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -510.72%. Cartesian Therapeutics' return on equity of 0.00% beat Apogee Therapeutics' return on equity.
Apogee Therapeutics has higher earnings, but lower revenue than Cartesian Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.
Apogee Therapeutics currently has a consensus target price of $89.71, suggesting a potential upside of 142.08%. Cartesian Therapeutics has a consensus target price of $42.86, suggesting a potential upside of 122.17%. Given Apogee Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Apogee Therapeutics is more favorable than Cartesian Therapeutics.
79.0% of Apogee Therapeutics shares are owned by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are owned by institutional investors. 36.1% of Apogee Therapeutics shares are owned by insiders. Comparatively, 57.9% of Cartesian Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Cartesian Therapeutics had 3 more articles in the media than Apogee Therapeutics. MarketBeat recorded 5 mentions for Cartesian Therapeutics and 2 mentions for Apogee Therapeutics. Cartesian Therapeutics' average media sentiment score of 0.46 beat Apogee Therapeutics' score of 0.20 indicating that Cartesian Therapeutics is being referred to more favorably in the news media.
Summary
Cartesian Therapeutics beats Apogee Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Cartesian Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cartesian Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:RNAC) was last updated on 1/20/2025 by MarketBeat.com Staff
Free RNAC Stock Alerts